Citations 184

EP25.05: Fetoscopic tracheal occlusion to regenerate fetal lungs in congenital diaphragmatic hernia

Ultrasound in Obstetrics & Gynecology | October 1, 2019 | Volume: 54 | Issue: S1 | Pages: 395-396

10.1002/uog.21642

The Regenerative Horizon: Opportunities for Nursing Research and Practice

Journal of Nursing Scholarship | October 1, 2019 | Volume: 51 | Issue: 6 | Pages: 651-660

10.1111/jnu.12520 | PMID 31566894

AbstractBackgroundRegenerative technologies aim to restore organ form and function. Technological advances in regenerative treatments have led to patients increasingly seeking these therapies. The readiness of nursing to fully contribute to this emerging healthcare field is uncertain.PurposeThe goal of this discipline‐oriented overview is to enhance awareness in the nursing community regarding regenerative science, and to provide suggestions for nursing research contributions and practice implications.MethodsEvolving and applied cutting‐edge therapies, such as regenerative immunotherapies with chimeric antigen receptor expressing T lymphocytes, are highlighted in the context of emerging opportunities for nurses in practice and research.DiscussionNext generation nurses will increasingly be at the forefront of new therapies poised to make chronic illnesses curable, thus restoring health and function to diverse groups of individuals.Clinical RelevanceThe regenerative care model imposes on the nursing community the imperative to (a) increase research awareness; (a) educate, develop, and deploy a skilled nursing workforce; (c) integrate regenerative technologies into nursing practice; and (d) embrace the regenerative technologies horizon as a future in health care.
Path Toward Proactive Therapy for Patent Ductus Arteriosus

Clinical Pharmacology & Therapeutics | August 21, 2019 | Volume: 106 | Issue: 6 | Pages: 1187-1190

10.1002/cpt.1583 | PMID 31433488

Ventricular remodeling in ischemic heart failure stratifies responders to stem cell therapy

Stem Cells Translational Medicine | August 2, 2019 | Volume: 9 | Issue: 1 | Pages: 74-79

10.1002/sctm.19-0149 | PMID 31373782

Abstract Response to stem cell therapy in heart failure is heterogeneous, warranting a better understanding of outcome predictors. This study assessed left ventricular volume, a surrogate of disease severity, on cell therapy benefit. Small to large infarctions were induced in murine hearts to model moderate, advanced, and end-stage ischemic cardiomyopathy. At 1 month postinfarction, cardiomyopathic cohorts with comparable left ventricular enlargement and dysfunction were randomized 1:1 to those that either received sham treatment or epicardial delivery of cardiopoietic stem cells (CP). Progressive dilation and pump failure consistently developed in sham. In comparison, CP treatment produced significant benefit at 1 month post-therapy, albeit with an efficacy impacted by cardiomyopathic stage. Advanced ischemic cardiomyopathy was the most responsive to CP-mediated salvage, exhibiting both structural and functional restitution, with proteome deconvolution substantiating that cell therapy reversed infarction-induced remodeling of functional pathways. Moderate cardiomyopathy was less responsive to CP therapy, improving contractility but without reversing preexistent heart enlargement. In end-stage disease, CP therapy showed the least benefit. This proof-of-concept study thus demonstrates an optimal window, or “Goldilocks principle,” of left ventricular enlargement for maximized stem cell-based cardiac repair. Disease severity grading, prior to cell therapy, should be considered to inform regenerative medicine interventions. Significance statement This article documents that cardiac chamber enlargement postinfarction is a predictor of cardiopoietic stem cell therapy response. Left ventricular size pretherapy could thus serve to guide the selection of ischemic heart failure candidates most suitable to receive a regenerative intervention.
Building the Regenerative Medicine Workforce of the Future: An Educational Imperative

Regenerative Medicine | July 25, 2019 | Volume: 14 | Issue: 7 | Pages: 613-615

10.2217/rme-2019-0072 | PMID 31342853

Regeneration for All: An Odyssey in Biotherapy

European Heart Journal | April 1, 2019 | Volume: 40 | Issue: 13 | Pages: 1033-1035

10.1093/eurheartj/ehz095 | PMID 30933287

Health Care Evolves From Reactive to Proactive

Clinical Pharmacology & Therapeutics | December 31, 2018 | Volume: 105 | Issue: 1 | Pages: 10-13

10.1002/cpt.1295 | PMID 30597564

Strontium‐substituted hydroxyapatite stimulates osteogenesis on poly(propylene fumarate) nanocomposite scaffolds

Journal of Biomedical Materials Research Part A | November 13, 2018 | Volume: 107 | Issue: 3 | Pages: 631-642

10.1002/jbm.a.36579 | PMID 30422387

Abstract Incorporation of hydroxyapatite (HA) into polymer networks is a promising strategy to enhance the mechanical properties and osteoinductivity of the composite scaffolds for bone tissue engineering. In this study, we designed a group of nanocomposite scaffolds based on cross‐linkable poly(propylene fumarate) (PPF) and 30 wt % strontium‐hydroxyapatite (Sr‐HA) nanoparticles. Four different Sr contents [Sr:(Sr + Ca), molar ratio] in the Sr‐HA particles were studied: 0% (HA), 5% (Sr5‐HA), 10% (Sr10‐HA), and 20% (Sr20‐HA). Two‐dimensional (2D) disks were prepared using a thermal crosslinking method. The structure and surface morphology of different Sr‐HA and PPF/Sr‐HA composites were characterized using scanning electron microscopy (SEM), energy‐dispersive X‐ray spectroscopy (EDS), transmission electron microscopy (TEM), and atomic force microscopy (AFM). To detect cellular responses in vitro, MC3T3‐E1 cells were seeded and cultured on the different PPF/Sr‐HA composite disks. Cell morphology after 24 h and 5 days were imaged using Live/Dead live cell staining and SEM, respectively. Cell proliferation was quantified using an MTS assay at 1, 4, and 7 days. Osteogenic differentiation of the cells was examined by alkaline phosphatase (ALP) staining at 10 days and quantified using ALP activity and osteocalcin assays at 7, 14, and 21 days. The sizes of the HA, Sr5‐HA, Sr10‐HA, and Sr20‐HA particles were mainly between 10 × 20 nm and 10 × 250 nm, and these nanoparticles were dispersed or clustered in the composite scaffolds. in vitro cell studies showed that the PPF/Sr10‐HA scaffold was significantly better than the other three groups (PPF/HA, PPF/Sr5‐HA, and PPF/Sr20‐HA) in supporting MC3T3‐E1 cell adhesion, proliferation, and differentiation. PPF/Sr10‐HA may, therefore, serve as a promising scaffold material for bone tissue engineering. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 107A: 631–642, 2019.
Regenerative Prophylaxis In Utero

Clinical Pharmacology & Therapeutics | November 12, 2018 | Volume: 105 | Issue: 1 | Pages: 39-41

10.1002/cpt.1262 | PMID 30417507

Mitochondria

Circulation Research | September 30, 2018 | Volume: 89 | Issue: 9 | Pages: 744-746

10.1161/res.89.9.744